Recursion Pharmaceuticals, Inc.

RXRX · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Assets
Cash & Equivalents$659,836$528,216$500,453$594,350
Short-Term Investments$0$0$0$0
Receivables$21,910$21,606$46,124$49,166
Inventory$0$0$0$0
Other Curr. Assets$32,359$37,338$37,568$70,753
Total Curr. Assets$714,105$587,160$584,145$714,269
Property Plant & Equip (Net)$181,244$193,604$204,777$233,213
Goodwill$162,042$164,270$158,112$148,873
Intangibles$322,344$341,319$335,790$335,855
Long-Term Investments$0$5,629$0$0
Tax Assets$957$957$2,003$1,934
Other NC Assets$18,834$9,416$20,407$14,454
Total NC Assets$685,421$715,195$721,089$734,329
Other Assets$0$0$0$0
Total Assets$1,399,526$1,302,355$1,305,234$1,448,598
Liabilities
Payables$13,935$19,314$25,086$21,613
Short-Term Debt$20,444$8,752$20,440$8,425
Tax Payable$0$0$0$0
Deferred Revenue$47,364$39,690$39,651$61,767
Other Curr. Liab.$73,360$1,537$56,804$50,853
Total Curr. Liab.$155,103$164,026$141,981$187,472
LT Debt$61,930$14,196$72,470$19,022
Deferred Rev, NC$0$126,243$0$118,765
Deferred Tax Liab, NC$23,312$23,784$22,437$16,575
Other NC Liab.$112,233$1,565$134,399$4,732
Total NC Liab.$197,475$219,183$229,306$226,344
Other Liabilities$0$0$0$0
Cap. Leases$61,553$65,127$67,877$81,045
Total Liabilities$352,578$383,209$371,287$413,816
Equity
Pref Stock$0$0$0$0
Common Stock$5$4$4$4
Retained Earnings-$1,967,879-$1,805,589-$1,633,694-$1,431,283
AOCI$34,093$43,620$14,145-$7,637
Other Equity$2,980,729$0$2,553,492$0
Total Equity$1,046,948$919,146$933,947$1,034,782
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$1,399,526$1,302,355$1,305,234$1,448,598
Net Debt-$577,462-$505,268-$407,543-$566,903
Recursion Pharmaceuticals, Inc. (RXRX) Financial Statements & Key Stats | AlphaPilot